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984 The Journal of Thoracic and CardioObjective: Surgical lung biopsy is considered the final method of diagnostic mo-
dality in patients with undiagnosed diffuse pulmonary disease. Nevertheless, the
effect of surgical lung biopsy on the diagnosis, treatment, and outcome of the patient
still remains controversial. This study reviewed the experiences of surgical lung
biopsies in 196 consecutive patients during the past 7 years.
Methods: Surgical lung biopsy was performed after achievement of general anes-
thesia through video-assisted thoracoscopic surgery or a 7-cm minithoracotomy.
Biopsy specimens were swabbed for aerobic and anaerobic bacterial, fungal, and
mycobacterial cultures. The sections of specimens were routinely stained with
hematoxylin and eosin, and acid-fast, Gomori methenamine silver, Gram stain, or
other special stains were added if necessary.
Results: The pathologic diagnosis after surgical lung biopsy included infection
(30.6%), interstitial pneumonia or fibrosis (21.9%), diffuse alveolar damage
(17.3%), neoplasm (13.3%), autoimmune diseases (8.2%), and others (8.2%). After
surgical lung biopsy, 165 (84.2%) patients had changes in their therapy, 124
(63.3%) patients had clinical improvement of their conditions, and 119 (60.7%)
patients survived to hospital discharge. Comparison between immunocompromised
and immunocompetent patients showed that diagnosis of infection was significantly
higher (P  .01) in the former group (41.2% vs 20.2%). In addition, there was no
significant difference in the distribution of diagnosis and rate of change in therapy
between the respiratory failure and nonrespiratory failure groups. However, the rates
of response to therapy and patient survival were significantly lower in the respira-
tory failure group (51.2% and 41.5%) than in the nonrespiratory failure group
(71.9% and 78.1%, P  .05). There was no surgical mortality directly related to the
procedure. The surgical morbidity rate was 6.6%.
Conclusion: Surgical lung biopsy is a safe and accurate diagnostic tool for diffuse
pulmonary disease. For a large proportion of the patients, change of therapy and
then clinical improvement can be achieved after surgical lung biopsy. Surgical lung
biopsy should be considered earlier in patients with undiagnosed diffuse pulmonary
disease, especially when the respiratory condition is deteriorating.
Diffuse pulmonary disease (DPD) is the result of a variety of causes and isusually accompanied by a greater or lesser degree of respiratory failure thatsometimes becomes a respiratory emergency.1-3 The majority of patients
are initially given diagnoses on the basis of images and noninvasive or minimally
invasive diagnostic procedures, such as echocardiography- or computed tomog-
raphy–guided biopsy, transbronchoscopic biopsy, or lavage. Nevertheless, defini-
tive diagnosis of lung lesions can sometimes not be made because of the inacces-
sibility of the true lesion or the inadequacy of the sample size.4-7 Surgical lung
biopsy (SLB) is considered the final diagnostic modality to be used in patients with
undiagnosed DPD. However, SLB has still been associated with substantial mor-
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TSbidity and mortality, even with advances in surgical tech-
niques and respiratory care.7,8 The effect of SLB on the
diagnosis, treatment, and outcome of the patient still re-
mains controversial.7,9,10 In this study we retrospectively
reviewed the experiences of SLBs in 196 consecutive pa-
tients in our institution during the past 7 years and looked
specifically at the distribution of diagnosis, effect on ther-
apy, and outcome of patients after SLB. The purpose of this
study was to determine whether SLB is worthwhile and for
which groups and when this procedure was more likely to
benefit patients.
Patients and Methods
During the period from November 1995 through March 2003, a
total of 196 patients with undiagnosed DPD underwent an open
lung biopsy (SLB) for the purposes of tissue diagnosis. The med-
ical records of these patients were retrospectively reviewed. These
included the following: demographic data; underlying condition;
clinical features; chest image study; status of respiratory function;
specific diagnostic test, including sputum examination and culture;
bronchoscopic examination; and related procedures, such as bron-
chial lavage or transbronchial biopsy. The duration from onset of
symptoms to the date of SLB in each patient was also collected.
The patients were classified as immunocompromised, including
(1) a primary diagnosis of malignancy for which the patient
received chemotherapy, radiation, or surgical intervention; (2)
receipt of organ transplantation with immunosuppressive therapy;
(3) diagnosis of collagen vascular disease or other autoimmune
diseases requiring corticosteroid or immunosuppressive therapy;
(4) presence of AIDS; and (5) presence of chronic renal failure. On
the other hand, according to the respiratory status, the patients
were defined as the respiratory failure group if they had symptoms
of respiratory insufficiency, a respiration rate of greater than 30
breaths/min, and a PaO2 of less than 60 mm Hg while breathing
room air and required supplemental oxygen or ventilator support
before SLB.
SLB was performed after achievement of general anesthesia
through video-assisted thoracoscopic surgery (VATS) or a 7-cm
minithoracotomy, which depended on the patient’s tolerance for sin-
gle-lung ventilation. The site and number of lung biopsy specimens
were determined by the findings on the chest radiographs or the
computed tomographic scans. Usually, 1 or 2 biopsy specimens,
triangular in shape, 2 to 3 cm in each margin, were obtained. For
VATS biopsy, 1 or 2 Endo GIA staples (Auto Suture Company
Division, U.S. Surgical, Norwalk, Conn) were used for securing the
pulmonary margins. For minithoracotomy, the lung specimen was cut
off after clamping proximally, and tissue was secured by 2 rows of
running sutures with 4-0 chromic catgut sutures. Biopsy specimens
were swabbed for aerobic and anaerobic bacterial, fungal, and myco-
bacterial cultures. The specimens were then sent to the pathologist for
freezing and permanent sectioning. Sections were routinely stained
with hematoxylin and eosin. Acid-fast, Gomori methenamine silver,
Gram stain, or other special stains were added if necessary. The
pathologic diagnosis of SLB was obtained. The operative morbidity
and mortality were recorded. The clinical diagnosis before the biopsy
was compared with the pathologic diagnosis of SLB. Three items of
variables were evaluated for each patient. Change in therapy indicated
The Journal of Thoracithat the original therapy had changed or stopped. Response to therapy
meant imaging and clinical improvements after the change in therapy.
Survival was interpreted as patient survival and discharge from the
hospital. Statistical analysis was done with the 2 test for the purposes
of comparison between groups.
Results
In total, 196 patients underwent SLB for DPD during the
study period. Eighty-seven patients were female, and 109
patients were male. The average age was 48.5 years (range,
6 months to 86 years). Among the 196 patients, 97 were
immunocompromised, and 99 were not. The distribution of
underlying diseases in the immunocompromised patients is
shown in Table 1. Among them, a total of 51 patients had
hematologic diseases, including neoplastic or myelosup-
pressive disorders, and 32 of them had previously under-
gone bone marrow transplantation (BMT). The duration
from BMT to the development of DPD varied from 0.5 to 44
months, with a mean of 3.2 months. According to the
patient’s respiratory condition, 82 patients belonged in the
respiratory failure or insufficiency group, and 114 patients
were in the respiratory nonfailure group. Before SLB, 26
patients had undergone echocardiography- or computed to-
mography–guided biopsy or transbronchoscopic biopsy, but
no conclusive diagnosis could be obtained. For SLB, VATS
Table 1. Underlying diseases in immunocompromised pa-
tients
Underlying disease
No. of
patients
Neoplastic disease 63
Leukemia 31
Solid tumors 19
Lymphoma 12
Multiple myeloma 1
Collagen or autoimmune disease 11
Dermatomyositis 4
Systemic lupus erythematosus 3
Polymyositis 1
Membranous glomerulonephritis 1
Giant cell arteritis 1
Behcet disease 1
Transplant recipient 7
Myelosuppressive diseases 8
Aplastic anemia 3
Myelodepressive syndrome 3
Fanconi syndrome 1
Thalassemia 1
Acquired immunodeficiency syndrome 4
Chronic renal failure 3
Ectopic ACTH hypersecretion 1
Total 97
ACTH, Adrenocorticotropic hormone.was used in 122 (62.2%) patients, and minithoracotomy was
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sites was 1 in 143 patients, 2 in 52 patients, and 3 in 1
patient.
The pathologic diagnosis after SLB is shown in Table 2.
The distribution of diagnosis was infection (30.6%), inter-
stitial pneumonia or fibrosis (21.9%), diffuse alveolar dam-
age (DAD; 17.3%), neoplasm (13.3%), autoimmune dis-
eases (8.2%), and others (8.2%). After open lung biopsy,
165 (84.2%) patients had changes in their therapy, 124
(63.3%) patients had clinical improvement in their condi-
tions (ie, response to the change in therapy), and 119
(60.7%) patients survived until hospital discharge. Five
patients eventually died as a result of late complications of
long-term steroid use, such as infection, sepsis, or upper
gastrointestinal tract bleeding, despite initial improvement
TABLE 2. Pathologic diagnosis of lung biopsy and effect o
Pathology
No. of patients
(n  196)
I. Infectious disease 60
CMV 21 (5)*
Tuberculosis 13
Organizing pneumonia 9
Pneumocystis species 5
Bacteria or viral pneumonia 5
Aspergillosis 4
Diffuse panbronchiolitis 2
Cryptococcosis 1
II. Interstitial pneumonia 43
NSIP 14
UIP 10
AIP 10
Honeycomb 9
III. Diffuse alveolar damage 34
IV. Neoplastic disease 26
Lymphoma 11
Primary lung cancer 7
Metastatic lung cancer 7
Hyalinizing granuloma 1
V. Autoimmune disease 16
BOOP or BO 6
Eosinophilic pneumonia 4
Acute capillaritis 3
Wegener granulomatosis 2
Sarcoidosis 1
VI. Alveolar proteinosis 6
VII. Lymphangioleiomyomatosis 4
VIII. Occupational disease 5
Asbestosis 3
Pneumoconiosis 1
Siderosis 1
IX. Pulmonary embolism 2
CMV, Cytomegalovirus; NSIP, nonspecific interstitial pneumonia; UIP, usu
obliterans organizing pneumonia; BO, bronchiolitis obliterans. *Mixed infefirst being noted. For the patients who had a change in
986 The Journal of Thoracic and Cardiovascular Surgery ● Maytherapy after SLB, the rate of patient survival (72.1%) was
significantly higher than that of those who had no change
(51.6%, P  .05) . The rates of change in therapy, response
to therapy, and patient survival in different groups of diag-
noses did not show any significant differences. Comparison
between immunocompromised and immunocompetent pa-
tients showed that diagnosis of infection was significantly
higher (P  .01) in the former group (41.2% vs 20.2%).
There were no significant differences in the rates of change
in therapy, response to therapy, and patient survival be-
tween these 2 groups (Table 3).
Comparison between the respiratory failure and nonfail-
ure groups showed that there were no significant differences
in the distribution of diagnosis and the rate of change in
therapy. However, the rates of response to therapy and
tient management
Change in
therapy, no. (%)
Response to
therapy, no. (%)
Survival,
no. (%)
55 (91.7) 40 (66.7) 41 (68.3)
19 (90.5) 11 (52.4) 11 (52.4)
13 (100) 10 (76.9) 10 (76.9)
6 (66.7) 5 (55.6) 6 (66.7)
5 (100) 3 (60.0) 3 (60.0)
5 (100) 5 (100) 5 (100)
4 (100) 3 (75.5) 3 (75.5)
2 (100) 2 (100) 2 (100)
1 (100) 1 (100) 1 (100)
42 (97.7) 28 (65.1) 26 (60.5)
13 (92.9) 13 (92.9) 13 (92.9)
10 (100) 6 (60.0) 5 (50.0)
10 (100) 6 (60.0) 6 (60.0)
9 (100) 3 (33.3) 2 (22.2)
29 (85.3) 21 (61.8) 18 (52.9)
17 (65.4) 14 (53.8) 15 (57.7)
8 (72.7) 7 (63.6) 7 (63.6)
4 (57.1) 3 (42.9) 3 (42.9)
5 (71.4) 4 (57.1) 4 (57.1)
0 1
15 (93.8) 14 (87.5) 14 (87.5)
6 (100) 6 (100) 6 (100)
4 (100) 4 (100) 4 (100)
3 (100) 3 (100) 2 (66.7)
2 (100) 1 (50.0) 1 (50.0)
0 1
5 (83.3) 5 (83.3) 5 (83.3)
0 4 (100)
5 (100)
0 3
0 1
0 1
2 (100) 2 (100) 2 (100)
rstitial pneumonia; AIP, acute interstitial pneumonia; BOOP: bronchiolitis
with Pneumocystis species (3), Aspergillus species (1), bacteria (1).n pa
al intepatient survival were significantly lower in the respiratory
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group (71.9% and 78.1%, P  .05). The differences were
mainly observed in the groups of patients with infection
(39.1% vs 83.8% and 34.8% vs 83.8%, P  .01) and
interstitial pneumonia (47.6% vs 81.8% and 42.9% vs
TABLE 3. Comparison between immunocompromised and
Immunocompromised (n  97)
Diagnosis
No. of
patients
Change in
therapy, no. (%)
Response to
therapy, no. (%)
Infectious disease 40 38 (95.0) 26 (65.0)
CMV 18 17 (94.4) 10 (55.6)
Tuberculosis 6 6 (100) 4 (66.7)
Pneumocystis
species
5 5 (100) 3 (60.0)
Others 11 10 (90.9) 9 (81.8)
Interstitial
pneumonia
21 20 (95.2) 16 (76.2)
NSIP 11 10 (90.9) 10 (90.9)
Honeycomb 6 6 (100) 2 (33.3)
UIP 2 2 (100) 2 (100)
AIP 2 2 (100) 2 (100)
Diffuse alveolar
damage
20 17 (85.0) 12 (60.0)
Autoimmune
disease
4 4 (100) 3 (75.0)
Neoplastic
disease
8 5 (62.5) 4 (50.0)
CMV, Cytomegalovirus; NSIP, nonspecific interstitial pneumonia; UIP, usu
TABLE 4. Comparison between patients with and without
Respiratory failure
Diagnosis
No. of
patients
Change in
therapy, no. (%)
Response to
therapy, no. (%)
Infectious disease 23 21 (91.3) 9 (39.1)
CMV 11 10 (90.9) 4 (36.4)
Pneumocystis
species
4 4 (100) 2 (50.0)
Tuberculosis 4 4 (100) 2 (50.0)
Others 4 3 (75.0) 1 (33.3)
Interstitial lung
disease
21 20 (95.2) 10 (47.6)
NSIP 6 5 (83.3) 5 (83.3)
AIP 6 6 (100) 3 (50.0)
Honeycomb 5 5 (100) 0 (0)
UIP 4 4 (100) 2 (50.0)
Diffuse alveolar
damage
24 21 (87.5) 15 (62.5)
Autoimmune
disease
5 5 (100) 4 (80.0)
Neoplastic
disease
5 3 (60.0) 1 (20.0)CMV, Cytomegalovirus; NSIP, nonspecific interstitial pneumonia; AIP, acute int
The Journal of Thoraci77.3%, P  .05; Table. 4) Thirty-two patients had earlier
undergone BMT for hematologic malignancies or myelo-
suppressive diseases. The results of SLB for diffuse pulmo-
nary lesions in these patients revealed inflammatory or
immunologic diseases in 16 patients, infectious diseases in
unocompetent patients
Immunocompetent (n  99)
rvival,
o. (%)
No. of
patients
Change in
therapy, no. (%)
Response to
therapy, no. (%)
Survival,
no. (%)
(62.5) 20 17 (85.0) 14 (70.0) 14 (70.0)
(50.0) 3 2 (66.7) 1 (33.3) 1 (33.3)
(66.7) 7 7 (100) 6 (85.7) 6 (85.7)
(60.0) 0
(81.8) 10 8 (80.0) 7 (70.0) 7 (70.0)
(71.4) 22 22 (100) 12 (54.5) 10 (45.5)
(90.9) 3 3 (100) 3 (100) 3 (100)
(33.3) 3 3 (100) 1 (33.3) 0 (0)
(50.0) 8 8 (100) 4 (50.0) 4 (50.0)
(100) 8 8 (100) 4 (50.0) 3 (37.5)
(40.0) 14 12 (85.7) 9 (64.3) 8 (57.1)
(50.0) 12 11 (91.7) 11 (91.7) 11 (91.7)
(50.0) 18 12 (66.7) 10 (55.6) 10 (55.6)
rstitial pneumonia; AIP, acute interstitial pneumonia.
iratory failure
Respiratory nonfailure
rvival,
o. (%)
No. of
patients
Change in
therapy, no. (%)
Response to
therapy, no. (%)
Survival,
no. (%)
(34.8) 37 34 (91.9) 31 (93.8) 31 (83.8)
(27.3) 10 9 (90.0) 7 (70.0) 7 (70.0)
(50.0) 1 1 (100) 1 (100) 1 (100)
(50.0) 9 9 (100) 8 (88.9) 8 (88.9)
(33.3) 17 15 (88.2) 15 (88.2) 15 (88.2)
(42.0) 22 22 (100) 18 (81.8) 17 (77.3)
(83.3) 8 8 (100) 8 (100) 8 (100)
(50.0) 4 4 (100) 3 (75.0) 3 (75.0)
(0) 4 4 (100) 3 (75.0) 2 (50.0)
(25.0) 6 6 (100) 4 (66.7) 4 (66.7)
(41.7) 10 8 (80.0) 6 (60.0) 6 (60.0)
(80.0) 11 11 (100) 10 (90.0) 9 (81.8)
(20.0) 21 14 (66.7) 13 (61.9) 13 (61.9)imm
Su
n
25
9
4
3
9
15
10
2
1
2
8
2
4resp
Su
n
8
3
2
2
1
9
5
3
0
1
10
4
1erstitial pneumonia; UIP, usual interstitial pneumonia.
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in 3 patients. Cytomegalovirus pneumonia accounted for
76.9% (10/13) of infections (Table 5). The result of treat-
ment of the infectious group showed a 38.5% (5/13) rate in
both response to therapy and patient survival, which was
comparatively lower than rates of 93.8% (15/16) and 81.3%
(13/16) for inflammatory and immunologic diseases (P 
.01 and P  .05).
Pulmonary tuberculosis accounted for 13 of 60 of the in-
fections. The prevalence was almost the same in the immuno-
compromised and nonimmunocompromised groups. Among
the 21 patients with a clinical diagnosis of tuberculosis before
SLB, only 3 had had a correct pathologic diagnosis. In the
other 10 patients with a final diagnosis of tuberculosis, tuber-
culosis was not suspected before SLB.
In this series, calculating from the date of onset of the
symptom to the date of SLB, 134 patients underwent SLB
before 30 days, and 62 patients underwent SLB after 30
days. There was no significant difference in the rate of
change in therapy, response to therapy, and patient survival
between these 2 groups.
In this study there was no surgical mortality directly
related to the procedure. Thirteen (6.6%) patients had sur-
gical morbidities, which included prolonged air leakage
(7 days) in 11 patients (7 in the minithoracotomy group
and 4 in the VATS group), hemothorax in 1 patient, and
acute myocardial infarction in 1 patient. Overall, 130 pa-
tients survived until hospital discharge. The in-hospital
mortality rate was 33.7% (66/196), and the 30-day mortality
rate was 24.0% (47/196).
Discussion
Although nonspecific diagnosis, such as DAD and inter-
TABLE 5. Result of open lung biopsy in 32 bone marrow
transplant recipients
Diagnosis
No. of
patients (%)
I. Inflammatory or immunologic 16 (50.0)
Interstitial pneumonia 10
Diffuse alveolar damage 3
Organizing pneumonia 1
Bronchiolitis obliterans 1
Acute capillaritis 1
II. Infectious 13 (40.6)
Cytomegalovirus 10
Tuberculosis 2
Pneumocystis species 1
III. Neoplastic 3 (9.4)
Lymphoma 2
PTLD 1
PTLD, Posttransplantation lymphoproliferative disorder.stitial pneumonia, accounted for a portion (39.3%) of
988 The Journal of Thoracic and Cardiovascular Surgery ● Maypathologic diagnoses in this series, for most patients
(60.7%), a specific diagnosis could only be made after
SLB. Infection, neoplastic disease, and autoimmune dis-
ease were among the most common specific diagnoses in
patients with DPD. This result is similar to most of the
recently reported series.1,7,9-11 The specific causes of
DAD usually cannot be determined from the histologic
findings. It can be identified through the information
from clinical history and laboratory data. In our experi-
ence of patients with DAD, once infectious causes could
be excluded by means of histologic examination and
tissue culture, corticosteroid therapy was added if the
condition of the patient did not improve after 1 to 2
weeks of antibiotic treatment and respiratory support. For
patients with a diagnosis of interstitial pneumonia, intra-
venous corticosteroid therapy (40-80 mg of methylpred-
nisolone every 6 hours) began after SLB. Among the
different types of interstitial pneumonia, the rate of re-
sponse to therapy and patient survival in nonspecific
interstitial pneumonia was comparatively higher. Gener-
ally, the rate of change in therapy, response to therapy,
and patient survival in patients with a diagnosis of DAD
or interstitial pneumonia was similar to those of patients
with a specific diagnosis. This result is similar to some of
the previous reports.1,2,12 In addition, the rate of change
in therapy in this series is considerably higher than that of
other studies.7 The beneficial effect of change in therapy
on patient survival was more obvious than in other re-
ports.1,3,9 This discrepancy can be explained by the fact
that we seldom performed a transbronchoscopic lavage or
biopsy before SLB in patients with undiagnosed DPD.
The diagnostic yield of bronchoscopic diagnostic proce-
dure is considerably lower than that of SLB4 and is not
without risk, especially in patients using mechanical ven-
tilation or with a bleeding tendency.13,14 In this series of
SLB, no operative mortality and only a few morbidities
were noted. Moreover, a less invasive VATS could have
been used for two thirds of the patients. Therefore, SLB
was considered earlier if the condition of the patients
with DPD deteriorated.
Infection was the most common diagnosis in immu-
nocompromised patients, and the rates of change in ther-
apy and patient survival were similar to those of immu-
nocompetent patients. The result was similar to those
seen in some of the previous reports.2,9 Although the
number of infectious causes was relatively low in immu-
nocompetent patients, the suggestion of a steroid trial
before SLB in immunocompetent patients should be
made with caution because infection still remains one of
the most common causes of diffuse pulmonary infiltrate.7
In this series, patients with respiratory failure had a
considerably lower rate of response to therapy and sur-
vival than did patients without failure, which is similar to
2005
Lee et al General Thoracic Surgery
G
TSresults seen in other studies.1,3,9,10 We believe that the
compromised condition, along with irreversible inflam-
matory changes in patients with respiratory failure, make
the diagnosis and treatment of DPD more difficult and
subsequently lead to mortality. It is suggested that pa-
tients with undiagnosed DPD should be considered for
SLB before the development of respiratory failure.
The result of SLB in patients with BMT showed a high
incidence of nonspecific diagnoses, such as interstitial
pneumonia or DAD. The cause was unclear but might be
related to previous irradiation, chemotherapy, or both; to
an undiagnosed viral infection; or to graft-versus-host
disease.15 This result is similar to the results of recent
reports.16-18 Nevertheless, the rate of response to change
of therapy and patient survival in this nonspecific diag-
nosis group is obviously better than in those with a
specific diagnosis, mostly because of cytomegalovirus
infection. This result is different from some previous
reports.16,18 The reason for such a difference is possibly
the inadequate surveillance for cytomegalovirus after
BMT in our hospital and also different spectrums of
histologic diagnosis in this series.19 Although it is gen-
erally accepted that the prognosis after SLB in patients
with BMT is obviously poor, our study did not show the
same result compared with other groups of patients.17,18
The difference might be explained by the principle of
early SLB, accurate diagnosis, and prompt treatment in
patients with BMT with undiagnosed DPD in our
institution.
Pulmonary tuberculosis remains one of the most com-
mon infectious diseases in Taiwan.20 In this study we
have found that pulmonary tuberculosis presenting with
DPD was sometimes difficult to diagnose by means of
sputum examination and imaging studies, such as chest
roentgenography and computed tomography. Pulmonary
tuberculosis presenting with DPD could occur in both
immunocompromised and immunocompetent patients.
SLB is very helpful for an accurate diagnosis of patients
with pulmonary tuberculosis presenting with DPD.
VATS was conducted in two thirds of the SLBs. It
provided good vision of the whole pleural cavity and a
greater selection of biopsy sites. It is generally accepted
that VATS biopsy reduces postoperative pain and dis-
ability, causes fewer operative scars, and is equally ef-
fective in obtaining histologic diagnosis.21,22 Therefore,
we believe that VATS should be considered as the first
priority for SLB. However, if the patient’s condition will
not allow him or her to tolerate single-lung ventilation or
if pleural adhesion is noted during the operation, VATS
should not be used for SLB.
It has been reported that SLB results in considerable
postoperative morbidities and mortalities, which might
run as high as 50%.8 In this study only a few postoper-
The Journal of Thoraciative complications were noted, and no operative death
occurred directly relating to the procedure. Most of the
hospital mortality was caused by disease progression,
secondary infection, or complications of the treatment.
In conclusion, SLB is an accurate diagnostic tool for
DPD with minimal operative morbidity and mortality. It
is helpful for a significant portion of patients in the
aspects of change in therapy and response to therapy. It
should be considered earlier in patients with undiagnosed
DPD, especially when the respiratory condition of the
patient is deteriorating.
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